Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$782.30M |
$3.85
-1.41%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$779.82M |
$19.20
+3.34%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$755.23M |
$40.21
-2.97%
|
|
EMBC
Embecta Corp.
Embecta operates as a medical device company focused on insulin injection devices, including pen needles, syringes, and safety products.
|
$746.27M |
$12.87
+0.86%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$737.00M |
$14.73
-1.80%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$732.56M |
$41.20
-7.42%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$726.88M |
$13.06
+0.62%
|
|
INNV
InnovAge Holding Corp.
InnovAge provides integrated care delivery and healthcare services at PACE centers and in-home settings, the core value proposition of their business.
|
$718.88M |
$5.31
-3.10%
|
|
PSNL
Personalis, Inc.
NeXT Personal is a tumor-informed liquid biopsy-based MRD test, central to PSNL's offerings.
|
$718.28M |
$8.10
-3.34%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$717.37M |
$4.33
+1.64%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$712.72M |
$7.45
-1.65%
|
|
CTKB
Cytek Biosciences, Inc.
Cytek's instrument manufacturing includes flow cytometry diagnostic equipment, the core product line referenced in the article.
|
$693.37M |
$5.47
+0.83%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$692.70M |
$7.23
-5.12%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$691.43M |
$12.98
-2.81%
|
|
ASPI
ASP Isotopes Inc. Common Stock
ASPI’s PET Labs Radiopharmaceuticals production and enriched isotopes are delivered as a core product line.
|
$690.27M |
$7.54
+17.08%
|
|
KE
Kimball Electronics, Inc.
KE's medical device and biometrics manufacturing capabilities are central to its strategy.
|
$686.59M |
$28.35
+0.04%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$677.13M |
$16.26
-0.91%
|
|
TCMD
Tactile Systems Technology, Inc.
Core medical devices for lymphedema and airway clearance (Flexitouch Plus, Nimbl, AffloVest) are manufactured and sold by the company.
|
$674.11M |
$30.04
-2.25%
|
|
TALK
Talkspace, Inc.
Talkspace is a behavioral health services provider delivering therapy to patients and payer networks.
|
$673.22M |
$4.03
-0.37%
|
|
BVS
Bioventus Inc.
Bioventus designs and manufactures medical devices and biometrics solutions for musculoskeletal health.
|
$663.91M |
$7.96
-0.56%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$659.48M |
$4.00
+0.50%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$656.25M |
$2.23
-0.22%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$643.91M |
$10.85
-2.60%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$626.79M |
$8.08
-1.82%
|
|
OFIX
Orthofix Medical Inc.
Core product category covering orthopedic implants and surgical devices, including spinal hardware.
|
$623.22M |
$15.79
-2.56%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$614.59M |
$88.31
-1.89%
|
|
SRDX
Surmodics, Inc.
Surmodics' vascular intervention devices (SurVeil DCB, Pounce thrombectomy, Sublime radial access) are a core product category sold by the company.
|
$614.58M |
$42.98
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$612.23M |
$6.50
-0.84%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$607.38M |
$7.40
-1.99%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$603.85M |
$1.97
|
|
LAB
Standard BioTools Inc.
CyTOF mass cytometry and Hyperion imaging systems are medical devices/biometrics platforms for advanced cellular analysis.
|
$588.27M |
$1.56
+1.30%
|
Showing page 16 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
